A new analysis by Kelly Scientific Publications of the global market for antibody-drug conjugates, bispecific monoclonal antibodies, cancer vaccines, chimeric antigen receptor or CAR T-cell therapy, PD-1/PD-L1 inhibitors, dendritic cells, and checkpoint inhibitors provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials.

Based on the available data, the overall market for cancer therapeutics stood at about $84.3 billion in 2014.  Immuno-therapeutics, including antibody-drug conjugates or ADCs, have gained acceptance because they are targeting cancer cells while surrounding healthy tissues remain unaffected.  As a result, these drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone.

The new report describes the evolution the market.


The report further provides an overview of cancer immunotherapy that include monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies, focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines, offers insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs, describes about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have been withdrawn from the market) and profiles marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe.

The report is supported by 155 tables & figures over 246 pages.